Does neurokinin-1-receptor antagonist aprepitant diminish the efficacy of cyclophosphamide-based chemotherapy?
Carlos Eduardo
CE
Paiva
Bianca Sakamoto Ribeiro
BS
Paiva
Odair Carlito
OC
Michelin
D000932:Antiemetics / Q000009:adverse effects* / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D000077608:Aprepitant; D001943:Breast Neoplasms / Q000188:drug therapy / Q000208:ethnology / Q000378:metabolism; D003520:Cyclophosphamide / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D009025:Morpholines / Q000009:adverse effects* / Q000627:therapeutic use; D064729:Neurokinin-1 Receptor Antagonists
D000932:Antiemetics; D018906:Antineoplastic Agents, Alkylating; D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists; D000077608:Aprepitant; C012358:4-hydroxycyclophosphamide; D003520:Cyclophosphamide